Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empire Prevent: Cardiac
NCT05084235Phase 2Completed
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in heart failure (HF). Started Sep 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05084235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084235.